Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

Area of Science:

• Immunology
• Oncology
• Genomics

Background:

• Immune checkpoint blockade therapies have transformed cancer treatment, particularly for advanced melanoma.
• However, many patients do not respond or eventually succumb to the disease, necessitating identification of response predictors and therapeutic targets.
• Understanding the tumor immune microenvironment is crucial for improving immunotherapy efficacy.

Purpose of the Study:

• To identify factors associated with the success or failure of immune checkpoint therapy in melanoma.
• To define distinct immune cell states within the tumor microenvironment that correlate with clinical outcomes.
• To discover novel targets for enhancing antitumor immunity.

Main Methods:

• Single-cell RNA sequencing (scRNA-seq) was performed on 16,291 immune cells from 48 melanoma patient tumor samples.
• Clustering analysis was used to define distinct CD8+ T cell states.
• Immunohistochemistry was used to visualize TCF7 expression in tumor samples, and epigenetic profiling was conducted.

Main Results:

• Two distinct CD8+ T cell states were identified, correlating with tumor regression or progression.
• TCF7 (T-cell factor 7) expression in CD8+ T cells emerged as a predictor of positive clinical outcome in an independent patient cohort.
• The epigenetic landscape and clonality of these T cell states were delineated, revealing potential vulnerabilities in exhausted T cells.

Conclusions:

• This study reveals distinct CD8+ T cell states associated with response to checkpoint inhibitors in melanoma.
• TCF7 is a potential predictive biomarker for immunotherapy response.
• Targeting novel combinations of factors in exhausted T cells may enhance antitumor immunity and improve patient outcomes.